Clinical trials: Recurrent Adamantinomatous Craniopharyngioma
Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2.
- Trial name
- NCT05286788
- Testing
- Binimetinib Oral Tablet [Mektovi]
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 38 people
- Sponsor
- Nationwide Children's Hospital
Adamantinomatous Craniopharyngioma
Tocilizumab in Children With ACP
This study will be conducted in two phases. The first phase (phase 0) will be looking at patients with new or recurrent/ progressed craniopharyngioma tumors.
- Trial name
- NCT03970226
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis.
- Trial name
- NCT05233397
- Testing
- Tocilizumab
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- Nationwide Children's Hospital